Protection by neuroglobin and cell-penetrating peptide-mediated delivery in vivo: A decade of research: Comment on Cai et al.: TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. Exp Neurol. 2011; 227(1): 224–31

详细信息    查看全文

• 作者：Gunnar P.H. Dietz ; ^a ; ^{gdietz@gwdg.de"" rel=""nofollow}
• 关键词：Hypoxia ; Ischemia ; Cell-penetrating peptide (CPP) ; Protein transduction domain (PTD) ; Stroke ; Transactivator of transcription (Tat) ; Antp (antennapedia)
• 刊名：Experimental Neurology
• 出版年：2011
• 出版时间：September 2011
• 年：2011
• 卷：231
• 期：1
• 页码：1-10
• 全文大小：273 K

文摘

Over the last decade, numerous studies have suggested that neuroglobin is able to protect against the effects of ischemia. However, such results have mostly been based on models using transgenic overexpression or viral delivery. As a therapy, new technology would need to be applied to enable delivery of high concentrations of neuroglobin shortly after the patient suffers the stroke. An approach to deliver proteins in ischemia in vivo in a timely manner is the use of cell-penetrating peptides (CPP). CPP have been used in animal models for brain diseases for about a decade as well. In a recent issue of Experimental Neurology, Cai and colleagues test the effect of CPP-coupled neuroglobin in an in vivo stroke model. They find that the fusion protein protects the brain against the effect of ischemia when applied before stroke onset. Here, a concise review of neuroglobin research and the application of CPP peptides in hypoxia and ischemia is provided.